A struggling Philadelphia-area biotech company that describes itself as a "leader in regenerative medicine," said today that Medtronic has participated in its effort to raise $31 million in financing.
A new opportunity for Medtronic
Fridley med-tech giant invests in a regenerative med firm
March 2, 2011 at 12:07AM
It's unclear from the news release how much Medtronic invested in Tengion Inc., but the Fridley-based med-tech giant gained "first refusal" on a technology called the New-Kidney Augment through October 2013. While that sounds more like an opening act at First Avenue to this blogger, the kidney product is designed to use a patient's own cells to replace kidney function, thus delaying or preventing the need for dialysis or a transplant. The product is still in the pre-clinical trials stage.
Janet Moore covers medical technology for the Star Tribune.
about the writer
janetmoore
Here's how to pick the right shovel, from the classic to the crack-jumper, back-saver or the plow.